AU2017207304B2 - Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone - Google Patents

Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone Download PDF

Info

Publication number
AU2017207304B2
AU2017207304B2 AU2017207304A AU2017207304A AU2017207304B2 AU 2017207304 B2 AU2017207304 B2 AU 2017207304B2 AU 2017207304 A AU2017207304 A AU 2017207304A AU 2017207304 A AU2017207304 A AU 2017207304A AU 2017207304 B2 AU2017207304 B2 AU 2017207304B2
Authority
AU
Australia
Prior art keywords
formulation
abdnaz
cancer
patient
whole blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017207304A
Other languages
English (en)
Other versions
AU2017207304A1 (en
Inventor
Scott CAROEN
Bryan T. Oronsky
Jan Scicinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epicentrx Inc
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of AU2017207304A1 publication Critical patent/AU2017207304A1/en
Application granted granted Critical
Publication of AU2017207304B2 publication Critical patent/AU2017207304B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2017207304A 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone Active AU2017207304B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277236P 2016-01-11 2016-01-11
US62/277,236 2016-01-11
PCT/US2017/012948 WO2017123593A1 (en) 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

Publications (2)

Publication Number Publication Date
AU2017207304A1 AU2017207304A1 (en) 2018-07-26
AU2017207304B2 true AU2017207304B2 (en) 2022-05-26

Family

ID=59311661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017207304A Active AU2017207304B2 (en) 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

Country Status (14)

Country Link
US (2) US11576895B2 (enExample)
EP (1) EP3402480B1 (enExample)
JP (1) JP6931004B2 (enExample)
KR (1) KR20190040931A (enExample)
CN (2) CN118236371A (enExample)
AU (1) AU2017207304B2 (enExample)
CA (1) CA3011103A1 (enExample)
DK (1) DK3402480T3 (enExample)
EA (1) EA201891606A1 (enExample)
ES (1) ES2880482T3 (enExample)
MX (1) MX2018008528A (enExample)
PL (1) PL3402480T4 (enExample)
SG (1) SG11201805942UA (enExample)
WO (1) WO2017123593A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
AU2017207304B2 (en) 2016-01-11 2022-05-26 Epicentrx, Inc. Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
CA3040479A1 (en) 2016-10-14 2018-04-19 Epicentrx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
IL311727A (en) 2017-07-07 2024-05-01 Epicentrx Inc Preparations for intravenous administration of medical substances
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
EP3801678A4 (en) 2018-06-11 2022-04-06 EpicentRx, Inc. MEDICATION INFUSION DEVICES, SYSTEMS AND METHODS
KR20220113996A (ko) 2019-12-11 2022-08-17 에피센트알엑스, 인코포레이티드 약제 주입 디바이스, 시스템 및 방법
TW202313001A (zh) * 2021-06-09 2023-04-01 美商埃皮辛特瑞科斯公司 結晶abdnaz組合物及其製造及使用方法
WO2023154480A1 (en) * 2022-02-10 2023-08-17 Epicentrx, Inc. Compositions and methods for treatment of nafld and nash and related dyslipidemias
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy
WO2024145484A1 (en) * 2022-12-29 2024-07-04 Epicentrx, Inc. Rrx-001 for treating reproductive-related disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308260A1 (en) * 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2978453A (en) 1956-12-12 1961-04-04 Aerojet General Co 3, 3, 5, 5-tetranitropiperidine
JPS4830376B1 (enExample) 1970-12-29 1973-09-19
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5511509A (en) * 1978-07-07 1980-01-26 Toomasu Gorudon Robaato Cancer therapy
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8728418D0 (en) 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5693794A (en) 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (ja) 1990-11-13 1997-09-30 株式会社日立製作所 表示制御装置
TW198712B (enExample) 1991-04-17 1993-01-21 Hoffmann La Roche
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1993008842A1 (en) 1991-11-08 1993-05-13 Somatogen, Inc. Hemoglobins as drug delivery agents
DE4226974C2 (de) 1992-08-14 1994-08-11 Fresenius Ag Verfahren und Vorrichtung zur kontinuierlichen Aufbereitung einer Zellsuspension
US5336784A (en) 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
JP3211892B2 (ja) 1994-05-27 2001-09-25 セイジィ ファーマスーティカルス インコーポレーテッド 肛門疾患を治療する窒素酸化物供与体及び方法
SK81197A3 (en) 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
ES2177771T3 (es) 1995-03-14 2002-12-16 Siemens Ag Dispositivo atomizador ultrasonico con unidad desmontable de dosificacion de precision.
ATE186222T1 (de) 1995-03-14 1999-11-15 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
AU5798996A (en) 1995-05-15 1996-11-29 Sachs, Michael C. Adnaz, compositions and processes
US5580988A (en) 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
JP2001501159A (ja) 1996-10-15 2001-01-30 イーストマン ケミカル カンパニー 爆薬配合物
US5945446A (en) 1997-02-10 1999-08-31 Laubc Biochemicals, Corporation Process for preparing synthetic soil-extract materials and medicaments based thereon
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
US7635722B1 (en) 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6391911B1 (en) 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
US20020077276A1 (en) 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
ES2244599T3 (es) 2000-04-10 2005-12-16 Pfizer Products Inc. Compuestos de benzamido-piperidina como antagonistas de la sustancia p.
JP2002069057A (ja) 2000-07-07 2002-03-08 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
RU2188026C1 (ru) 2001-01-12 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака почки
DE10111049A1 (de) 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
AU2002359918A1 (en) 2001-12-28 2003-07-24 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003282534A1 (en) 2002-10-07 2004-05-04 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
US6870061B2 (en) 2003-01-10 2005-03-22 Alliant Techsystems Inc. Continuous process and system for production of glycidyl nitrate from glycerin, nitric acid and caustic and conversion of glycidyl nitrate to poly(glycidyl nitrate)
EP1603933A2 (en) 2003-03-13 2005-12-14 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
WO2004113281A1 (en) 2003-06-25 2004-12-29 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
AU2004257693B8 (en) 2003-07-09 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
RU2265440C2 (ru) 2004-01-13 2005-12-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ предоперационного лечения рака молочной железы
US7829708B2 (en) 2004-09-08 2010-11-09 Chelsea Therapeutics, Inc. Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation
US20060264415A1 (en) 2005-04-01 2006-11-23 Methylgene Inc. Inhibitors of histone deacetylase
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2007038459A2 (en) 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
FR2891843A1 (fr) 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
CN200946766Y (zh) 2006-06-09 2007-09-12 刘余厚 一种套管式紫外灯
US8122281B2 (en) 2007-04-13 2012-02-21 International Business Machines Corporation System and method for dependent failure-aware allocation of distributed data-processing systems
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
AU2009234127B2 (en) 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
US9867782B2 (en) 2009-04-09 2018-01-16 Entegrion, Inc. Spray-dried blood products and methods of making same
CN102458112A (zh) 2009-04-10 2012-05-16 阿布拉科斯生物科学有限公司 纳米颗粒制剂及其用途
CN101708337B (zh) 2009-08-18 2011-08-10 上海交通大学医学院附属新华医院 一种包载奥沙利铂的人血白蛋白纳米粒的制备方法
RU2411953C1 (ru) 2009-09-02 2011-02-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт" Федерального агентства по высокотехнологичной мед. помощи Способ лечения рака молочной железы
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US20120149678A1 (en) * 2010-12-09 2012-06-14 Oronsky Bryan T Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
EP2763667B1 (en) 2011-10-07 2022-10-26 EpicentRx, Inc. Organonitro thioether compounds and medical uses thereof
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
US9694015B2 (en) 2012-09-10 2017-07-04 Celgene Corporation Methods for the treatment of locally advanced breast cancer
WO2015030730A1 (en) 2013-08-27 2015-03-05 Halliburton Energy Services, Inc. Energetic cocrystals for treatment of a subterranean formation
US20140220163A1 (en) 2014-02-04 2014-08-07 Hamzeh Soleimani Babadi Powder mixture composition of natural materials for controlling deficiencies in polypeptide alpha and beta hemoglobin chains
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
AU2017207304B2 (en) 2016-01-11 2022-05-26 Epicentrx, Inc. Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
CA3040479A1 (en) 2016-10-14 2018-04-19 Epicentrx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
IL311727A (en) 2017-07-07 2024-05-01 Epicentrx Inc Preparations for intravenous administration of medical substances
KR20200128659A (ko) 2018-01-08 2020-11-16 에피센트알엑스, 인코포레이티드 방사선방호를 위해 RRx-001을 이용하는 방법 및 조성물
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
EP3801678A4 (en) 2018-06-11 2022-04-06 EpicentRx, Inc. MEDICATION INFUSION DEVICES, SYSTEMS AND METHODS
KR20220113996A (ko) 2019-12-11 2022-08-17 에피센트알엑스, 인코포레이티드 약제 주입 디바이스, 시스템 및 방법
US20230364112A1 (en) 2020-09-29 2023-11-16 Alps Biotech Co., Ltd. Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases
CN114621125B (zh) 2020-12-14 2024-07-09 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用
TW202313001A (zh) 2021-06-09 2023-04-01 美商埃皮辛特瑞科斯公司 結晶abdnaz組合物及其製造及使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308260A1 (en) * 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FITCH et al., "High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain", 44th Western Regional Meeting of the American Chemical Society, (2013-10-03), *
SCICINSKI et al., "Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent", Drug Metabolism and Disposition, (2012), vol. 40, no. 9, pages 1810 - 1816 *

Also Published As

Publication number Publication date
EP3402480A4 (en) 2019-09-18
BR112018014027A2 (pt) 2018-12-11
CN118236371A (zh) 2024-06-25
EP3402480A1 (en) 2018-11-21
US12357607B2 (en) 2025-07-15
CN109069420A (zh) 2018-12-21
AU2017207304A1 (en) 2018-07-26
ES2880482T3 (es) 2021-11-24
US20230233524A1 (en) 2023-07-27
WO2017123593A1 (en) 2017-07-20
JP2019505585A (ja) 2019-02-28
EA201891606A1 (ru) 2019-02-28
PL3402480T3 (pl) 2021-11-22
MX2018008528A (es) 2019-05-16
PL3402480T4 (pl) 2021-11-22
CA3011103A1 (en) 2017-07-20
JP6931004B2 (ja) 2021-09-01
KR20190040931A (ko) 2019-04-19
US20190307723A1 (en) 2019-10-10
SG11201805942UA (en) 2018-08-30
EP3402480B1 (en) 2021-03-24
US11576895B2 (en) 2023-02-14
DK3402480T3 (da) 2021-06-28

Similar Documents

Publication Publication Date Title
US12357607B2 (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
CN104274442A (zh) 癌症的治疗
CN115025090A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
TWI302912B (en) Therapeutic use
WO2020236668A1 (en) Leukadherin-1 alone or in combination for use in the treatment of cancer
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
JP2023509191A (ja) 癌を治療するための組み合わせ療法
EP3534902B1 (en) Combinations of fgfr4 inhibitors and bile acid sequestrants
HK40000756B (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
BR112018014027B1 (pt) Formulação intravenosa contendo abdnaz para administração intravenosa a um paciente e uso
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
EA043426B1 (ru) Способ лечения злокачественного новообразования и внутривенный препарат, содержащий abdnaz
Michniewicz et al. DIPG-83. Using copper chelating agents to target receptor tyrosine kinase signalling in diffuse intrinsic pontine glioma (DIPG)
US20250049802A1 (en) Combination therapies and uses for treating cancer
Nayak, MD et al. CTNI-63. PRELIMINARY SAFETY AND EFFICACY OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
Duke et al. DIPG-80. CLINICAL AND RADIOGRAPHIC RESPONSE TO ONC201 IN A PEDIATRIC PATIENT WITH A THALAMIC H3K27M AND BRAFV600E MUTANT DIFFUSE MIDLINE HIGH GRADE GLIOMA
Lippens Methotrexate in the central nervous system prophylaxis of children with acute lymphoblastic leukemia
Saito et al. DDDR-03. DEVELOPMENT OF ANTI-TUMOR AROMA THERAPY FOR GLIOBLASTOMA WITH LEMONGRASS ESSENTIAL OIL
DIFFUSE DIPG-80. CLINICAL AND RADIOGRAPHIC RESPONSE TO ONC201 IN A PEDIATRIC PATIENT WITH A THALAMIC H3K27M AND BRAFV600E MUTANT DIFFUSE MIDLINE HIGH GRADE GLIOMA
Cortes et al. CML-387 ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results
BR112019008787B1 (pt) Combinações de inibidores de fgfr4 e sequestrantes de ácido biliar, e seus usos
JPWO2023083868A5 (enExample)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)